Semax is a synthetic heptapeptide derived from the ACTH 4-10 fragment — a region of adrenocorticotropic hormone with known cognitive effects but no adrenal activity. Developed by the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s and later approved in Russia for stroke recovery and cognitive enhancement, Semax has one of the more credible research backgrounds in the nootropic peptide space, with both mechanistic data and human clinical applications.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Semax primarily upregulates BDNF (brain-derived neurotrophic factor) in the hippocampus and frontal cortex, promoting synaptic plasticity, memory consolidation, and neuroplasticity. It also modulates monoamine systems (dopamine, serotonin, norepinephrine) and has neuroprotective and anti-inflammatory effects. Users typically report improved focus, sharper memory, enhanced learning capacity, and better stress resilience.
How Does Semax Work?
Semax's primary mechanism involves upregulation of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus and frontal cortex. BDNF is the key growth factor for synaptic plasticity, learning, and memory consolidation — it's essentially the molecular signal that drives neuroplasticity. Low BDNF is associated with depression, cognitive decline, and poor stress resilience. Semax appears to elevate BDNF consistently in animal models, which provides a mechanistic basis for its reported cognitive effects.
Secondary mechanisms include effects on the monoamine systems — Semax modulates dopamine, serotonin, and norepinephrine transmission in ways consistent with improved focus and stress response. It also has documented anti-inflammatory effects in the CNS, relevant to both stroke recovery (its clinical application) and general neuroprotection.
The intranasal route is effective because the nasal mucosa provides direct access to the CNS via the olfactory pathway, bypassing the blood-brain barrier. This is why Semax is typically administered intranasally rather than by injection — higher brain bioavailability, lower systemic exposure.
Clinical Use in Russia and Research Evidence
Semax has been used in Russian clinical medicine since the 1990s, primarily for stroke recovery, TBI, and cognitive impairment. This clinical use provides more human exposure data than most research peptides, though the peer-reviewed literature is predominantly in Russian and not always accessible in translation.
Key published findings: Semax reduced infarct size in ischemic stroke models and improved neurological outcomes in acute stroke patients in clinical use. It improved performance on cognitive testing in patients with memory impairment. It showed antidepressant effects in animal models and improved stress resilience in rodent studies.
The BDNF upregulation finding has been replicated across multiple labs and is considered one of the more reliable mechanisms in the peptide nootropic space. Whether the magnitude of BDNF elevation at typical research doses translates to clinically meaningful cognitive improvement in healthy subjects is the key open question.
What Is the Recommended Semax Dosage?
| Form | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Semax (standard) | 200–600 mcg | Intranasal | 1–2x daily | Most common protocol |
| NA-Semax (N-acetyl) | 100–300 mcg | Intranasal | 1–2x daily | More potent — start lower |
| NA-Semax Amidate | 100–200 mcg | Intranasal | 1x daily | Most potent form |
| SubQ injection | 200–500 mcg | SubQ | 1x daily | Less common but effective |
Side Effects and Considerations
Semax is generally well-tolerated with a mild side effect profile. The most common reports:
**Mild stimulation:** Increased alertness and energy, particularly on first use. Can interfere with sleep if taken too late in the day. Most protocols keep dosing to morning or early afternoon.
**Appetite suppression:** Mild and transient, usually resolves after the first week.
**Nasal irritation:** From intranasal administration — mild burning or irritation in some users. Usually resolved by diluting the solution slightly or alternating nostrils.
**Mood effects:** Predominantly positive — reduced anxiety, improved mood, better stress resilience. Occasionally reports of restlessness or irritability at higher doses.
**Cycling:** Most protocols run 2–4 week cycles with breaks. The concern with continuous BDNF upregulation is theoretical — some researchers believe maintaining chronically elevated BDNF may reduce receptor sensitivity. The cycling approach is precautionary rather than evidence-based.
**Stacking:** Semax is commonly combined with Selank for complementary anxiolytic + cognitive enhancement effects. Selank's GABA-modulatory calming effect pairs well with Semax's stimulating cognitive enhancement.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Semax primarily upregulates BDNF (brain-derived neurotrophic factor) in the hippocampus and frontal cortex, promoting synaptic plasticity, memory consolidation, and neuroplasticity. It also modulates monoamine systems (dopamine, serotonin, norepinephrine) and has neuroprotective and anti-inflammatory effects. Users typically report improved focus, sharper memory, enhanced learning capacity, and better stress resilience.
No. Semax is approved for clinical use in Russia and some Eastern European countries for stroke recovery and cognitive impairment. It has no FDA approval and is classified as a research chemical in the US, Canada, and most Western countries. It can be purchased for research purposes from peptide vendors.
Semax is primarily cognitive-enhancing and mildly stimulating, working mainly through BDNF and monoamine systems. Selank is primarily anxiolytic (reduces anxiety), working through GABA-A modulation and enkephalin stabilization. Many users combine them for a balanced nootropic + anxiolytic stack. Semax is better for focus and cognitive load; Selank is better for anxiety and social situations.
NA-Semax (N-Acetyl Semax) has an acetyl group added to the N-terminus that increases resistance to enzymatic degradation, extending half-life and potency. Most researchers consider it more potent than regular Semax on a per-dose basis, requiring lower doses for equivalent effects. NA-Semax Amidate (also amidated at the C-terminus) is the most potent and longest-acting form.
Semax is typically reconstituted in bacteriostatic water or sterile saline, drawn into a nasal atomizer or sterile dropper, and administered as drops or a fine mist into each nostril. Typical volume is 25–50 mcL per nostril. Tilt head back slightly after administration to allow absorption. Avoid blowing nose for 10 minutes after dosing.
Semax is generally reported to reduce anxiety rather than cause it, through its serotonin and dopamine modulatory effects. Some users at higher doses report mild restlessness or overstimulation. If anxiety is a concern, starting at a low dose and stacking with Selank is the standard community approach.